As such, combining PBNP-PTT with MYC targeting via drugs such as I-BET726 or JQ1 in MYCN-amplified neuroblastoma cells may generate immunogenicity more similar to that seen in SH-SY5Y cells, and may provide effective treatment for high-risk neuroblastoma patients with MYCN amplification. This evidence concerns the gene MYCN and neuroblastoma.